| DC10516 |
LW6(CAY10585)
Featured
|
CAY10585 prevented HIF-1 transcriptional activity with IC50 values of 2.6 and 0.7 µM, respectively. |
|
| DC20607 |
Cazpaullone |
Cazpaullone (9-Cyano-1-azapaullone) is a derivative of 1-Azakenpaullone, a potent, selective GSK3β inhibitor with IC50 of 8 nM, weakly inhibits CDK1/cyclin B and CDK5/p25 (IC50=0.5 and 0.3 uM). |
|
| DC22986 |
CB5305630 |
CB5305630 is a potent and noncompetitive IRE1 RNase inhibitor with IC50 of 60 nM in the FRET-derepression assay. |
|
| DC20861 |
CB-618 |
CB-618 (CB 238618) is a novel non-β-lactam β-lactamase inhibitor that potentiates meropenem MIC values against clinical Enterobacteriaceae isolates. |
|
| DC20862 |
CB-618 sodium salt |
CB-618 (CB 238618) is a novel non-β-lactam β-lactamase inhibitor that potentiates meropenem MIC values against clinical Enterobacteriaceae isolates. |
|
| DC20052 |
CB-6644
Featured
|
CB-6644 is a selective inhibitor of RUVBL1/2 complex with anti-cancer activity. CB-6644 blocks the ATPase activity of RUVBL1/2 with an IC50 of 15 nM. |
|
| DC20863 |
CB-6673567 |
CB-6673567 is a potent, selective Adenylyl Cyclase 1 (AC1) inhibitor with IC50 of 77 uM, displays a 2- to 4-fold isoform selectivity over AC6. |
|
| DC10449 |
CB7921220
Featured
|
CB7921220 is an inhibitor of Adenylyl Cyclase isoform-1 (AC1) and isoform-6 (AC6). |
|
| DC8042 |
CB-839(Telaglenastat)
Featured
|
CB-839 is a potent, selective, reversible and orally bioavailable inhibitor of human glutaminase. |
|
| DC12623 |
CBK289001 |
CBK289001 (CBK-289001) is a small molecule inhibitor of Tartrate-resistant acid phosphatase (TRAP/ACP5), demonstrates efficacy in a migration assay and IC50 values from 4 to 125 uM.. |
|
| DC20866 |
CC-671
Featured
|
CC-671 is a potent, selective, dual TTK (Mps1)/CLK2 inhibitor with IC50 of 5/3 nM, respectively. |
|
| DC12532 |
CC-90003 |
CC-90003 (CC90003) is a potent and selective, covalent ERK1/2 inhibitor with IC50 of 10-20 nM, demonstrates excellent selectivity in a 258-kinase biochemical assay panel. |
|
| DC12590 |
CCB 02
Featured
|
CCB02 (CCB 02) is a specific small molecule inhibitor of CPAP-tubulin interaction with IC50 of 0.689 uM in AlphaScreen assay, selectively binds at the CPAP binding site of tubulin. |
|
| DC23540 |
CCC07-01 |
CCC07-01 (CCC 0701) is a novel alkylating compound that is capable of disrupting expression of PD-1, PD-L1 and CTLA-4 genes with IC50 of 15, 10 and 5 nM in cell-base assays. |
|
| DC7319 |
CCDC(TGR5-Receptor-Agonist)
Featured
|
CCDC is a otent, selective TGR5 G-protein coupled receptor agonist (pEC50 = 6.8). |
|
| DC20867 |
CCG 102487 |
CCG 102487 is a CCG-2979 analog that reduces streptokinase (SK) activity with little inhibition of group A streptococcal (GAS) growth. |
|
| DC20871 |
CCG 2979 |
CCG 2979 is a small molecule inhibitor of gene expression of streptokinase (SK), a critical group A streptococcal (GAS) virulence factor. |
|
| DC7979 |
CCG1423
Featured
|
CCG-1423 is a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis. |
|
| DC10535 |
CCG-203971
Featured
|
CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50 = 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM. |
|
| DC10977 |
CCG-222740 |
CCG-222740 (CCG222740) is a pharmacological inhibitor of MRTF/SRF signalling, shows greater inhibitory effect on MRTF/SRF target genes than MRTF-A inhibitor CCG-203971, with IC50 of 5 uM in fibroblast-mediated collagen contraction assay. |
|
| DC20869 |
CCG-232601 |
CCG-232601 is a potent (IC50=0.55 uM), orally bioavailable Rho/MKL1/SRF transcriptional pathway that target transcriptional factor MRTF. |
|
| DC22819 |
CCG-50014
Featured
|
CCG-50014 is the most potent against the regulator of G-protein signaling protein type 4 (RGS4) (IC50 =30 nM) and is >20-fold selective for RGS4 over other RGS proteins. CCG-50014 binds covalently to the RGS, forming an adduct on two cysteine residues located in an allosteric regulatory site. CCG50014, reduces nociceptive responses and enhances opioid-mediated analgesic effects in the mouse formalin test. |
|
| DC22050 |
CCI-006 |
CCI-006 (CCI 006) is a novel inhibitor of MLL-rearranged and CALM-AF10 translocated leukemias that share common leukemogenic pathways. |
|
| DC22049 |
CCI-007 |
CCI-007 (CCI 007) is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia with IC50 of 3.5 uM against MLL-r leukemia cell line PER-485. |
|
| DC26030 |
CCMI
Featured
|
CCMI is a positive allosteric modulator of α7 neuronal nicotinic acetylcholine receptors (nAChR). |
|
| DC12639 |
CCR1 inhibitor 19e |
CCR1 inhibitor 19e is a novel potent, selective CCR1 antagonist with IC50 of 6.8 nM, inhibits CCR1chemotaxis in THP-1 cells with IC50 of 28 nM.. |
|
| DC23528 |
CCR10 antagonist 1 |
CCR10 antagonist 1 is a potent, selective CCR10 antagonist with IC50 of 690 nM. |
|
| DC12177 |
CCR2 antagonist 1 |
CCR2 antagonist 1 is a high-affinity and long-residence-time CCR2 antagonist, with a Ki of 2.4 nM. |
|
| DC12302 |
CCR2 antagonist 3
Featured
|
CCR2 antagonist 3 is a chemokine receptor 2 (CCR2) antagonist. |
|
| DC20876 |
CCT 068127 |
CCT 068127 (CCT68127) is a novel potent inhibitor of CDK2 and CDK9 with IC50 of 10 and 90 nM for CDK2/E and CDK9/T, respectively. |
|
